Cantor Fitzgerald L. P. Makes New Investment in Equillium, Inc. $EQ

Cantor Fitzgerald L. P. bought a new position in Equillium, Inc. (NASDAQ:EQ) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 425,000 shares of the company’s stock, valued at approximately $608,000.

Several other large investors have also modified their holdings of EQ. ADAR1 Capital Management LLC acquired a new position in Equillium in the third quarter worth about $7,951,000. Woodline Partners LP bought a new stake in Equillium in the third quarter valued at about $5,018,000. Vanguard Group Inc. raised its stake in Equillium by 59.4% during the third quarter. Vanguard Group Inc. now owns 1,313,946 shares of the company’s stock valued at $1,879,000 after buying an additional 489,855 shares in the last quarter. Aberdeen Group plc acquired a new stake in Equillium during the third quarter valued at approximately $543,000. Finally, Two Sigma Investments LP bought a new position in Equillium during the 3rd quarter worth approximately $190,000. Institutional investors own 27.05% of the company’s stock.

Insider Activity

In related news, COO Christine Zedelmayer sold 120,312 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $2.50, for a total transaction of $300,780.00. Following the completion of the transaction, the chief operating officer owned 62,586 shares in the company, valued at $156,465. The trade was a 65.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders sold 594,001 shares of company stock valued at $1,148,895. Company insiders own 31.60% of the company’s stock.

Equillium Stock Down 0.9%

Shares of EQ stock opened at $2.13 on Thursday. The company has a market cap of $129.70 million, a P/E ratio of -3.44 and a beta of 1.81. The business has a 50 day moving average of $1.59 and a two-hundred day moving average of $1.42. Equillium, Inc. has a 52 week low of $0.27 and a 52 week high of $2.70.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Stifel Nicolaus initiated coverage on Equillium in a research report on Wednesday, February 25th. They issued a “buy” rating and a $5.00 target price for the company. Zacks Research raised Equillium to a “hold” rating in a research report on Thursday, February 26th. Roth Mkm initiated coverage on Equillium in a research note on Friday, March 13th. They set a “buy” rating and a $12.00 price objective on the stock. Wall Street Zen raised shares of Equillium from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Equillium in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Equillium presently has an average rating of “Hold” and a consensus price target of $6.00.

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.